Myriad Genetics (MYGN) EBT (2009 - 2026)

Myriad Genetics has disclosed EBT across 18 years of filings, most recently posting -$34.1 million for Q1 2026.

• In Q1 2026, EBT fell 15.99% year-over-year to -$34.1 million; the TTM figure through Mar 2026 stood at -$399.8 million (down 215.05% YoY), while the FY2025 annual figure was -$395.1 million, down 219.92% from the prior year.
• EBT fell to -$34.1 million in Q1 2026, from -$8.9 million in the prior quarter.
• Over the last five years, EBT for MYGN reached as high as -$8.9 million in Q4 2025 and fell as low as -$330.6 million in Q2 2025.
• The 5-year median for EBT is -$34.1 million (2026), against an average of -$56.2 million.
• The widest YoY moves for EBT: up 77.24% in 2025, down 788.71% in 2025.
• A 5-year view of EBT shows it stood at -$52.1 million in 2022, then soared by 38.0% to -$32.3 million in 2023, then fell by 21.05% to -$39.1 million in 2024, then soared by 77.24% to -$8.9 million in 2025, then tumbled by 283.15% to -$34.1 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$34.1 million, -$8.9 million, and -$26.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.